MY206964A - Tricyclic akr1c3 dependent kars inhibitors - Google Patents

Tricyclic akr1c3 dependent kars inhibitors

Info

Publication number
MY206964A
MY206964A MYPI2021006666A MYPI2021006666A MY206964A MY 206964 A MY206964 A MY 206964A MY PI2021006666 A MYPI2021006666 A MY PI2021006666A MY PI2021006666 A MYPI2021006666 A MY PI2021006666A MY 206964 A MY206964 A MY 206964A
Authority
MY
Malaysia
Prior art keywords
kars
tricyclic
inhibitors
akr1c3
dependent
Prior art date
Application number
MYPI2021006666A
Inventor
Ariel Sterling Twomey
Nik Savage
Katsumasa Nakajima
Marie-Helene Larraufie
Yuko Isome
Christy Fryer
Jian Ding
Tracy Chen
Chris Adair
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY206964A publication Critical patent/MY206964A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor. The most suitable drawing: FIG. 1.
MYPI2021006666A 2019-08-01 2020-07-31 Tricyclic akr1c3 dependent kars inhibitors MY206964A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962881619P 2019-08-01 2019-08-01
US202063009513P 2020-04-14 2020-04-14
US202063033932P 2020-06-03 2020-06-03
PCT/IB2020/057285 WO2021005586A1 (en) 2019-08-01 2020-07-31 Tricyclic akr1c3 dependent kars inhibitors

Publications (1)

Publication Number Publication Date
MY206964A true MY206964A (en) 2025-01-22

Family

ID=71994691

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021006666A MY206964A (en) 2019-08-01 2020-07-31 Tricyclic akr1c3 dependent kars inhibitors

Country Status (37)

Country Link
US (3) US11970497B2 (en)
EP (2) EP4013500B1 (en)
JP (1) JP7008161B2 (en)
KR (1) KR102735388B1 (en)
CN (1) CN114206870B (en)
AU (1) AU2020309846B2 (en)
BR (1) BR112022001308A2 (en)
CA (1) CA3139940A1 (en)
CL (1) CL2022000201A1 (en)
CO (1) CO2022000370A2 (en)
CR (1) CR20220031A (en)
CU (1) CU24698B1 (en)
DK (1) DK4013500T3 (en)
DO (1) DOP2022000010A (en)
EC (1) ECSP22005621A (en)
ES (1) ES2969591T3 (en)
FI (1) FI4013500T3 (en)
HR (1) HRP20231734T1 (en)
HU (1) HUE064882T2 (en)
IL (1) IL287792B2 (en)
JO (1) JOP20220020B1 (en)
LT (1) LT4013500T (en)
MA (1) MA71308A (en)
MX (1) MX2022000961A (en)
MY (1) MY206964A (en)
PE (1) PE20220343A1 (en)
PH (1) PH12022550200A1 (en)
PL (1) PL4013500T3 (en)
PT (1) PT4013500T (en)
PY (1) PY2039449A (en)
RS (1) RS65068B1 (en)
SA (1) SA522431533B1 (en)
SI (1) SI4013500T1 (en)
TW (1) TWI864063B (en)
UY (1) UY38806A (en)
WO (1) WO2021005586A1 (en)
ZA (1) ZA202108632B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3983413A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
JP7667097B2 (en) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ.ベー. Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators - Patents.com
UY38806A (en) 2019-08-01 2021-02-26 Novartis Ag AKR1C3-DEPENDENT KARS TRICYCLIC INHIBITOR COMPOUNDS, COMPOSITIONS AND THEIR USES
IL300833A (en) 2020-09-02 2023-04-01 Ascentawits Pharmaceuticals Ltd Akr1c3 detection method, and diagnostic kit for detecting akr1c3 and use thereof
CN113135878A (en) * 2021-04-09 2021-07-20 新沂市凯美斯特医药科技有限公司 Method for synthesizing 3-aminomethyl tetrahydrofuran by taking furan as raw material
PT4334289T (en) 2021-05-07 2025-09-01 Organon R&D Finland Oy Novel heterocyclic compounds, compositions, methods of preparation and uses thereof
CN115403579A (en) * 2021-05-27 2022-11-29 上海拓界生物医药科技有限公司 Novel spiro derivative and application thereof
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
CN118804755A (en) * 2022-06-10 2024-10-18 深圳艾欣达伟医药科技有限公司 Methods of treating cancer patients with AKR1C3 enzyme-activated prodrugs
CN119421704A (en) 2022-07-26 2025-02-11 诺华股份有限公司 Pharmaceutical composition of tricyclic AKR1C3-dependent KARS inhibitor and preparation method thereof
US20260007654A1 (en) 2022-07-26 2026-01-08 Novartis Ag Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention
JP2025524064A (en) 2022-07-26 2025-07-25 ノバルティス アーゲー Crystalline forms of AKR1C3-dependent KARS inhibitors
KR20260020475A (en) 2023-06-06 2026-02-11 아센타위츠 파마슈티컬즈 리미티드 Correlation between AKR1C3 enzyme expression levels and KRAS mutations and their medical applications.
CN121985960A (en) 2023-10-18 2026-05-05 深圳艾欣达伟医药科技有限公司 Treatment of patients with negative P53 gene mutation, positive KRAS gene mutation, and positive BRCA mutation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476019B1 (en) * 1999-08-13 2002-11-05 Sepracor Inc. Spirocyclic ligands for sigma receptors, and libraries and methods of use thereof
WO2006023821A2 (en) * 2004-08-20 2006-03-02 The Trustees Of Columbia University In The City Of New York Ligands for aldoketoreductases
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
UY33779A (en) * 2010-12-10 2012-07-31 Boehringer Ingelheim Int ? 2- (Phenylamino) -1H-benzimidazol-5-carboxamides novel?
US9346803B2 (en) * 2011-10-17 2016-05-24 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
WO2016145092A1 (en) 2015-03-10 2016-09-15 Threshold Pharmaceuticals, Inc. Dna alkylating agents
US10167293B2 (en) * 2016-05-26 2019-01-01 Bayer Pharma Aktiengesellschaft [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones
CN113226464A (en) * 2018-12-18 2021-08-06 诺华股份有限公司 N- (pyridin-2-ylsulfonyl) cyclopropanecarboxamide derivatives and their use in the treatment of CFTR mediated diseases
UY38806A (en) * 2019-08-01 2021-02-26 Novartis Ag AKR1C3-DEPENDENT KARS TRICYCLIC INHIBITOR COMPOUNDS, COMPOSITIONS AND THEIR USES

Also Published As

Publication number Publication date
ECSP22005621A (en) 2022-02-25
CO2022000370A2 (en) 2022-01-28
PY2039449A (en) 2021-12-20
AU2020309846B2 (en) 2023-12-14
JP2021527113A (en) 2021-10-11
EP4013500B1 (en) 2023-10-25
TW202120507A (en) 2021-06-01
US20240262827A1 (en) 2024-08-08
EP4349839A3 (en) 2024-10-02
US20250179072A1 (en) 2025-06-05
JOP20220020A1 (en) 2023-01-30
PT4013500T (en) 2024-01-11
CA3139940A1 (en) 2021-01-14
LT4013500T (en) 2024-01-25
HUE064882T2 (en) 2024-04-28
DK4013500T3 (en) 2024-01-02
SA522431533B1 (en) 2024-04-16
CU24698B1 (en) 2024-03-05
US11970497B2 (en) 2024-04-30
ZA202108632B (en) 2024-09-25
MA71308A (en) 2025-04-30
CN114206870A (en) 2022-03-18
PH12022550200A1 (en) 2022-11-14
HRP20231734T1 (en) 2024-03-15
CU20220005A7 (en) 2022-09-08
IL287792A (en) 2022-01-01
BR112022001308A2 (en) 2022-05-17
ES2969591T3 (en) 2024-05-21
AU2020309846A1 (en) 2022-01-06
EP4349839A2 (en) 2024-04-10
US20220315582A1 (en) 2022-10-06
MX2022000961A (en) 2022-02-14
RS65068B1 (en) 2024-02-29
PE20220343A1 (en) 2022-03-14
IL287792B2 (en) 2025-04-01
TWI864063B (en) 2024-12-01
KR20220025845A (en) 2022-03-03
CL2022000201A1 (en) 2022-11-18
IL287792B1 (en) 2024-12-01
DOP2022000010A (en) 2022-03-15
JP7008161B2 (en) 2022-01-25
UY38806A (en) 2021-02-26
CN114206870B (en) 2024-09-03
WO2021005586A1 (en) 2021-01-14
CR20220031A (en) 2022-02-09
FI4013500T3 (en) 2024-01-19
JOP20220020B1 (en) 2024-12-22
KR102735388B1 (en) 2024-11-29
SI4013500T1 (en) 2024-02-29
PL4013500T3 (en) 2024-03-25
EP4013500A1 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
SA522431533B1 (en) Tricyclic akr1c3 dependent kars inhibitors
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
PH12017500583B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
SA518392101B1 (en) Benzimidazole Derivatives as Modulators of ROR-GAMMA
MX2018006223A (en) Modulators of ror-gamma.
PH12016500094A1 (en) Autotaxin inhibitors
EP4520395A3 (en) Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
PH12021550872A1 (en) Therapeutic compounds
MY209035A (en) Tricyclic compounds and their use
PH12021550901A1 (en) Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
WO2016178092A3 (en) C-3 novel triterpenone with c-28 reverse amide derivatives as hiv inhibitors
EA202191955A1 (en) MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS
MX2023005076A (en) Interleukin-17 inhibitors.
WO2017134685A3 (en) Novel hydrazino compounds as btk inhibitors
PH12021550258A1 (en) Cdk8/19 inhibitors
MX379327B (en) Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
ZA202100955B (en) Thrombin inhibitors, formulations, and uses thereof
EA201992151A1 (en) PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY